Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Accured Expenses (2016 - 2025)

Ironwood Pharmaceuticals' Change in Accured Expenses history spans 16 years, with the latest figure at -$141000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 99.55% year-over-year to -$141000.0; the TTM value through Dec 2025 reached $4.0 million, up 119.62%, while the annual FY2025 figure was $4.0 million, 119.62% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$141000.0 at Ironwood Pharmaceuticals, down from $249000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $25.9 million in Q3 2024 and bottomed at -$31.6 million in Q4 2024.
  • The 5-year median for Change in Accured Expenses is -$2.2 million (2021), against an average of -$377850.0.
  • The largest annual shift saw Change in Accured Expenses surged 784.12% in 2022 before it crashed 1876.74% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$2.5 million in 2021, then soared by 784.12% to $16.9 million in 2022, then crashed by 117.75% to -$3.0 million in 2023, then plummeted by 952.1% to -$31.6 million in 2024, then skyrocketed by 99.55% to -$141000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Change in Accured Expenses are -$141000.0 (Q4 2025), $249000.0 (Q3 2025), and -$5.8 million (Q2 2025).